NEW YORK (TheStreet) -- Shares of Cerner Corp. (CERN - Get Report) are dropping by 14.15% to $47.61 in after-hours trading on Tuesday, after the Kansas City, MO-based company reported its 2015 fourth quarter earnings.
After today's market close, the health care information technology supplier reported adjusted earnings of 61 cents per diluted share, topping analysts' expectations for earnings of 57 cents per share.
Revenue for the period was $1.175 billion, slightly higher than analysts' estimates of $1.17 billion.
"Our fourth quarter results reflect a solid finish to a record year," President Zane Burke said in a statement. "In 2015, we added more than double the number of new EHR clients than any year in our history, including both large health systems and small hospitals."
For the first quarter, Cerner expects earnings per share between 52 cents and 54 cents on revenue in the range of $1.15 billion and $1.2 billion.
The company forecasts adjusted earnings per diluted share between $2.30 and $2.40 on revenue in the range of $4.9 billion and $5.1 billion for the full year.
Cerner offers a range of intelligent solutions and services that support the clinical, financial and operational needs of organizations, including software, hardware, professional services and managed services.
Separately, TheStreet Ratings Team has a "Buy" rating with a score of B on the stock.
This is driven by several positive factors, which should have a greater impact than any weaknesses, and should give investors a better performance opportunity than most stocks covered.
The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, growth in earnings per share and increase in net income.
The team believes its strengths outweigh the fact that the company has had lackluster performance in the stock itself.
Recently, TheStreet Ratings objectively rated this stock according to its "risk-adjusted" total return prospect over a 12-month investment horizon. Not based on the news in any given day, the rating may differ from Jim Cramer's view or that of this articles's author.
You can view the full analysis from the report here: CERNCERN data by YCharts